Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

SIRT6 Suppresses Cancer Stem-like Capacity in Tumors with PI3K Activation Independently of Its Deacetylase Activity.

Ioris RM, Galié M, Ramadori G, Anderson JG, Charollais A, Konstantinidou G, Brenachot X, Aras E, Goga A, Ceglia N, Sebastián C, Martinvalet D, Mostoslavsky R, Baldi P, Coppari R.

Cell Rep. 2017 Feb 21;18(8):1858-1868. doi: 10.1016/j.celrep.2017.01.065.

2.

Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung Tumorigenesis.

Padanad MS, Konstantinidou G, Venkateswaran N, Melegari M, Rindhe S, Mitsche M, Yang C, Batten K, Huffman KE, Liu J, Tang X, Rodriguez-Canales J, Kalhor N, Shay JW, Minna JD, McDonald J, Wistuba II, DeBerardinis RJ, Scaglioni PP.

Cell Rep. 2016 Aug 9;16(6):1614-1628. doi: 10.1016/j.celrep.2016.07.009. Epub 2016 Jul 28.

3.

Molecular Basis of the Rapamycin Insensitivity of Target Of Rapamycin Complex 2.

Gaubitz C, Oliveira TM, Prouteau M, Leitner A, Karuppasamy M, Konstantinidou G, Rispal D, Eltschinger S, Robinson GC, Thore S, Aebersold R, Schaffitzel C, Loewith R.

Mol Cell. 2015 Jun 18;58(6):977-88. doi: 10.1016/j.molcel.2015.04.031. Epub 2015 May 28.

4.

Diet-induced unresolved ER stress hinders KRAS-driven lung tumorigenesis.

Ramadori G, Konstantinidou G, Venkateswaran N, Biscotti T, Morlock L, Galié M, Williams NS, Luchetti M, Santinelli A, Scaglioni PP, Coppari R.

Cell Metab. 2015 Jan 6;21(1):117-25. doi: 10.1016/j.cmet.2014.11.020. Epub 2014 Dec 18.

5.

RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas.

Konstantinidou G, Ramadori G, Torti F, Kangasniemi K, Ramirez RE, Cai Y, Behrens C, Dellinger MT, Brekken RA, Wistuba II, Heguy A, Teruya-Feldstein J, Scaglioni PP.

Cancer Discov. 2013 Apr;3(4):444-57. doi: 10.1158/2159-8290.CD-12-0388. Epub 2013 Jan 28.

6.

p130Cas/Cyclooxygenase-2 axis in the control of mesenchymal plasticity of breast cancer cells.

Bisaro B, Montani M, Konstantinidou G, Marchini C, Pietrella L, Iezzi M, Galiè M, Orso F, Camporeale A, Colombo SM, Di Stefano P, Tornillo G, Camacho-Leal MP, Turco E, Taverna D, Cabodi S, Amici A, Defilippi P.

Breast Cancer Res. 2012 Oct 26;14(5):R137. doi: 10.1186/bcr3342.

7.

The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.

Rabellino A, Carter B, Konstantinidou G, Wu SY, Rimessi A, Byers LA, Heymach JV, Girard L, Chiang CM, Teruya-Feldstein J, Scaglioni PP.

Cancer Res. 2012 May 1;72(9):2275-84. doi: 10.1158/0008-5472.CAN-11-3159. Epub 2012 Mar 9.

8.

Translation-dependent mechanisms lead to PML upregulation and mediate oncogenic K-RAS-induced cellular senescence.

Scaglioni PP, Rabellino A, Yung TM, Bernardi R, Choi S, Konstantinidou G, Nardella C, Cheng K, Pandolfi PP.

EMBO Mol Med. 2012 Jul;4(7):594-602. doi: 10.1002/emmm.201200233. Epub 2012 Mar 21.

9.

Mesenchymal/stromal gene expression signature relates to basal-like breast cancers, identifies bone metastasis and predicts resistance to therapies.

Marchini C, Montani M, Konstantinidou G, Orrù R, Mannucci S, Ramadori G, Gabrielli F, Baruzzi A, Berton G, Merigo F, Fin S, Iezzi M, Bisaro B, Sbarbati A, Zerani M, Galiè M, Amici A.

PLoS One. 2010 Nov 30;5(11):e14131. doi: 10.1371/journal.pone.0014131.

10.

Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.

Konstantinidou G, Bey EA, Rabellino A, Schuster K, Maira MS, Gazdar AF, Amici A, Boothman DA, Scaglioni PP.

Cancer Res. 2009 Oct 1;69(19):7644-52. doi: 10.1158/0008-5472.CAN-09-0823. Epub 2009 Sep 29.

11.

CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor.

Scaglioni PP, Yung TM, Choi S, Baldini C, Konstantinidou G, Pandolfi PP.

Mol Cell Biochem. 2008 Sep;316(1-2):149-54. doi: 10.1007/s11010-008-9812-7. Epub 2008 Jun 20. Erratum in: Mol Cell Biochem. 2009 Jul;327(1-2):279. Choi, S C [corrected to Choi, S].

PMID:
18566754
12.

Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice.

Galiè M, Konstantinidou G, Peroni D, Scambi I, Marchini C, Lisi V, Krampera M, Magnani P, Merigo F, Montani M, Boschi F, Marzola P, Orrù R, Farace P, Sbarbati A, Amici A.

Oncogene. 2008 Apr 17;27(18):2542-51. Epub 2007 Nov 12.

PMID:
17998939

Supplemental Content

Loading ...
Support Center